We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis (ABA3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04380740
Recruitment Status : Recruiting
First Posted : May 8, 2020
Last Update Posted : October 26, 2022
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Leslie Kean, Boston Children's Hospital

Brief Summary:
This is a multicenter randomized, double blind, Phase 2 trial for patients receiving transplants from 7 of 8 HLA matched donors, in which an extended dosing regimen of abatacept, and a short-term dosing regimen + placebo, when added to standard calcineurin inhibitor + methotrexate-based prophylaxis, will be compared for their ability to improve outcomes in patients with a minimum follow-up of one year post-transplant. All patients will receive 4 doses of abatacept (Days -1, +5, +14, +28). Prior to the fifth dose, patients will be randomly assigned to the 4-dose abatacept arm and receive 4 doses of placebo or 8-dose abatacept arm and receive 4 more doses of abatacept. The primary endpoint of the study will be severe AGVHD-free, severe CGVHD-free, relapse-free survival (SGRFS). The study will end when the last patient has reached 2 years after transplant. Results will first be calculated and the study unblinded when the last patient has reached one year post-transplant.

Condition or disease Intervention/treatment Phase
Graft Vs Host Disease Drug: Placebo Drug: Abatacept Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 160 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized Double-Blind Trial of Abatacept Extended Dosing Versus Abatacept Short-term Dosing for Graft Versus Host Disease Prophylaxis: "ABA3"
Actual Study Start Date : March 30, 2022
Estimated Primary Completion Date : April 2024
Estimated Study Completion Date : April 2025

Resource links provided by the National Library of Medicine

Drug Information available for: Abatacept

Arm Intervention/treatment
Placebo Comparator: Standard GVHD Prophylaxis + Abatacept + Placebo
Standard GVHD prophylaxis of calcineurin inhibitor (cyclosporine or tacrolimus) and methotrexate + 4 doses of Abatacept (investigational product) + 4 doses of Placebo.
Drug: Placebo
During the extended dosing of abatacept, those randomized to receive 4 doses will receive a placebo consisting of an equal volume of normal saline solution.
Other Name: saline

Drug: Abatacept
Investigational prophylaxis with extended-dosing abatacept, a calcineurin inhibitor and methotrexate.
Other Name: orencia

Experimental: Standard GVHD Prophylaxis + Abatacept Extended dosing
Standard GVHD prophylaxis of calcineurin inhibitor (cyclosporine or tacrolimus) and methotrexate + 8 doses of Abatacept.
Drug: Abatacept
Investigational prophylaxis with extended-dosing abatacept, a calcineurin inhibitor and methotrexate.
Other Name: orencia




Primary Outcome Measures :
  1. Severe AGVHD-free, severe CGVHD-free, relapse-free survival (SGRFS) [ Time Frame: 2 years ]
    SGRFS will be modeled as a time-to-event outcome, and as such, failures that occur beyond one year and before study end will be considered in the analysis.


Secondary Outcome Measures :
  1. Severe Chronic GVHD [ Time Frame: 2 years ]
    We will compare the cause-specific hazards of severe chronic GVHD, including overlap syndrome (based on adjudicated events), using the NIH consensus criteria, between the two arms of the study.

  2. Relapse-Free survival [ Time Frame: 2 years ]
    We will compare the hazards of failure (earliest of relapse or any-cause death) for relapse-free survival (RFS), which will be defined as survival without relapse of underlying malignancy.

  3. Non-relapse mortality [ Time Frame: 2 years ]
    We will compare the cause-specific hazards of non-relapse mortality (NRM), which will be defined as death without a prior relapse, with relapse defined as either morphological or standard cytogenetic evidence of acute leukemia or MDS consistent with pre-transplant features, or radiologic evidence of lymphoma, documented or not by biopsy.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Must be at least 2 years old and weigh 10 kg.
  2. Must have a willing unrelated adult donor (bone marrow or peripheral blood). Donors may have a single mismatch (i.e. be a 7/8) and this mismatch may be at the allele or antigen level; however, donors with allele level disparity should be given preference over those with antigen level disparity. Patients for whom a donor is available with disparity only in the host versus graft direction (because of recipient homozygosity), will not be eligible, since this mismatching does not increase the risk for GVHD. Centers may perform extended typing (e.g. DQB1 and DPB1) according to institutional practices and use these results in selecting donors; however, it is recommended that this extending typing be used only to select between donors who are equally well matched with the recipient at the A, B, C and DRB1.
  3. All patients and/or their parents or legal guardians must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines.
  4. Must have a hematologic malignancy treatable by HCT (except for those stipulated below under study Exclusion Criteria), which is in remission by standard testing (no patients in relapse will be included).
  5. Patients with an inherited predisposition to leukemia or otherwise hematologic malignancies that have not been associated with predisposition to transplant morbidities or non-hematologic cancers.
  6. Karnofsky performance score or Lanskey Play-Performance Scale score >/= 80.

    • If the patient does not meet defined eligibility requirements, the PI/study committee must be contacted to determine eligibility.

Exclusion Criteria:

  1. Patients with the following hematologic malignancies will be excluded: Chronic Lymphocytic Leukemia, Myeloma and Primary Myelofibrosis.
  2. Active Relapse (>5% blasts) of their primary malignancy.
  3. For patients with Acute Lymphocytic Leukemia (ALL) with pre-transplant MRD testing performed as standard practice at the treating institution, patients with MRD >0.01% will be ineligible.
  4. For patients with Acute Myeloid Leukemia (AML) with pre-transplant MRD testing as standard of practice at the treating institution, patients with any MRD status are eligible and should be enrolled at the discretion of provider.
  5. For patients with MDS, those with >5% blasts will be excluded.
  6. Prior allogeneic HCT.
  7. Uncontrolled viral, bacterial, fungal or protozoal infection at the time of study enrollment.
  8. HIV infection.
  9. Serious psychiatric disease including schizophrenia, bipolar disorder and severe depression.
  10. Prisoners or others who are compulsorily detained.
  11. Any patient with a known or suspected inherited predisposition to cancer should be discussed with the study team prior to screening for eligibility.

    1. Patients with a known inherited or constitutional predisposition to transplant morbidities, including, but not limited to Fanconi Anemia, Dyskeratosis Congenita, Shwachman-Diamond Syndrome and Down Syndrome will be excluded.
    2. Patients with known inherited or constitutional predisposition to non-hematologic cancers including, but not limited to Li-Fraumeni syndrome, BRCA1 and BRCA2 mutations will be excluded.
  12. Patients with active non-hematological malignancies (except non-melanoma skin cancers) or those with non-hematological malignancies (except non-melanoma skin cancers) who have been rendered with no evidence of disease, and are disease free for <2 years.
  13. Incompletely treated active tuberculosis Infection.
  14. Pregnancy (positive serum b-HCG) or breastfeeding.
  15. Estimated GFR of < 50 mL/min/1.73m2.
  16. Cardiac ejection fraction < 50 (using M-Mode if assessment is done by ECHO)
  17. T.bilirubin > 2 × upper limit of normal or ALT > 4 × upper limit of normal or unresolved veno-occlusive disease.
  18. Pulmonary disease with FVC, FEV1 or DLCO parameters <45% predicted (corrected for hemoglobin) or requiring supplemental oxygen. Children who are developmentally unable to perform pulmonary function testing will be assessed solely on their need for supplemental oxygen.
  19. Presence of antibodies to a mismatched donor HLA antigen (please refer to Section 3.4.g).
  20. Patients who have developed severe AGVHD, severe CGVHD or relapse will be excluded at the time of randomization.
  21. Exclusion Criteria Prior to Randomization (prior to 5th dose of abatacept/placebo):

    1. Severe allergic reaction during the first 4 doses of abatacept
    2. If any clinical events occur that preclude further dosing of abatacept, those patients will be deemed ineligible for randomization

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04380740


Contacts
Layout table for location contacts
Contact: Brandi M Bratrude, BA 6179192197 brandi.bratrude@childrens.harvard.edu

Locations
Layout table for location information
United States, California
City Of Hope National Medical Center Recruiting
Duarte, California, United States, 91010
Contact: Monzr M Al Malki, MD       malmalki@coh.org   
Principal Investigator: Monzr M Al Malki, MD         
United States, Georgia
Emory University/Winship Cancer Center Recruiting
Atlanta, Georgia, United States, 30322
Contact: Amelia Langston, MD       amelia.langston@emory.edu   
Principal Investigator: Amelia Langston, MD         
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: Zachariah DeFilipp, MD       zdefilipp@mgh.harvard.edu   
Principal Investigator: Zachariah Defilipp, MD         
Boston Children's Hospital Recruiting
Boston, Massachusetts, United States, 02115
Contact: Brandi Bratrude, BA    617-919-2197    brandi.bratrude@childrens.harvard.edu   
Principal Investigator: Leslie S Kean, MD, PhD         
Beth Israel Deaconess Medical Center Recruiting
Boston, Massachusetts, United States, 02215
Contact: Ajoy Dias, MD       adias3@bidmc.harvard.edu   
Principal Investigator: Ajoy Dias, MD         
Dana-Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
Contact: Roman Shapiro, MD       roman_shapiro@dfci.harvard.edu   
Principal Investigator: Roman Shapiro, MD         
United States, Michigan
University of Michigan Recruiting
Ann Arbor, Michigan, United States, 48109
Contact: Sung Choi, MD       sungchoi@med.umich.edu   
Principal Investigator: Sung Choi, MD         
United States, Ohio
Cincinnati Children's Hospital Recruiting
Cincinnati, Ohio, United States, 45229
Contact: Michael Grimley, MD       michael.grimley@cchmc.org   
Principal Investigator: Michael Grimley, MD         
Sponsors and Collaborators
Boston Children's Hospital
Bristol-Myers Squibb
Layout table for additonal information
Responsible Party: Leslie Kean, Director, Stem Cell Transplantation Program, Division of Hematology/Oncology, Boston Children's Hosptial, Boston Children's Hospital
ClinicalTrials.gov Identifier: NCT04380740    
Other Study ID Numbers: IRB-P00035528
20-227 ( Other Identifier: Dana-Farber Cancer Institute )
First Posted: May 8, 2020    Key Record Dates
Last Update Posted: October 26, 2022
Last Verified: October 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The Dana-Farber/Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscripts may only be shared under the terms of a Data Use Agreement. Requests may be directed to aba3study@childrens.harvard.edu. The protocol and statistical analysis plan will be made available on clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Time Frame: Data can be shared no earlier that 1 year following the date of publication.
Access Criteria: Contact the Technology & Innovation Development Office at www.childrensinnovations.org or email TIDO@childrens.harvard.edu

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Graft vs Host Disease
Immune System Diseases
Abatacept
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents